The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
Jing Zou, Xuping Xie, Camila R. Fontes-Garfias, Kena A. Swanson, Isis Kanevsky, Kristin Tompkins, Mark Cutler, David Cooper, Philip R. Dormitzer, Pei‐Yong Shi
Abstract
Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7-2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.
Topics & Concepts
VirologyNeutralizationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)MutationVirusClinical trial2019-20 coronavirus outbreakMedicineBiologyImmunologyGeneticsBioinformaticsInternal medicineGeneDiseaseInfectious disease (medical specialty)OutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies